Eiger discontinues ubenimex for PAH

Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) discontinued development of ubenimex to treat pulmonary arterial hypertension (PAH). The company made the decision after the product missed the primary endpoint in

Read the full 278 word article

User Sign In